Enveric Biosciences (FRA:SLZ0) Total Liabilities: €0.40 Mil (As of Mar. 2026)


FRA:SLZ0 Enveric Biosciences Inc FRA:SLZ0
30 GF Score
Price €56.07
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences Total Liabilities?

Enveric Biosciences FRA:SLZ0 30 Total Liabilities is €0.40 Mil as of Mar. 2026. GuruFocus rates FRA:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Enveric Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was €0.40 Mil.

Enveric Biosciences's quarterly Total Liabilities increased from Sep. 2025 (€0.77 Mil) to Dec. 2025 (€0.78 Mil) but then declined from Dec. 2025 (€0.78 Mil) to Mar. 2026 (€0.40 Mil).

Enveric Biosciences's annual Total Liabilities declined from Dec. 2023 (€2.15 Mil) to Dec. 2024 (€1.42 Mil) and declined from Dec. 2024 (€1.42 Mil) to Dec. 2025 (€0.78 Mil).

Enveric Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences Total Liabilities Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.91 3.77 2.15 1.42 0.78

Enveric Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.18 0.77 0.78 0.40
FRA:SLZ0
30GF Score
Enveric Biosciences Inc FRA:SLZ0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Enveric Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.784+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.78

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=4.352-3.568
=0.78

Enveric Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.399+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.40

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=4.776-4.378
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.40 Mil mean?
Enveric Biosciences (FRA:SLZ0) has a Total Liabilities of €0.40 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Enveric Biosciences and its competitors.
Is Enveric Biosciences' Total Liabilities too high?
Enveric Biosciences' current Total Liabilities is €0.40 Mil. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' Total Liabilities compare to APVO and CNSP?
Enveric Biosciences' Total Liabilities of €0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Enveric Biosciences and its competitors. Enveric Biosciences's current Total Liabilities is €0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (FRA:SLZ0) has a current Total Liabilities of €0.40 Mil. The current Total Liabilities is €0.40 Mil. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Enveric Biosciences (FRA:SLZ0), the current Total Liabilities is €0.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score

Get the complete analysis for FRA:SLZ0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.07
Price